论文部分内容阅读
本文着重就美国肿瘤研究机构,特别是国立肿瘤研究所(NCI)对一些抗癌新药进行临床研究的概况作一简要的综述。如所周知,自1954年以来,NCI负责组织和协调美国各地癌的化学控制方面的研究,从事大量物质的抗癌作用筛选试验。仅在1972年,NCI就试验30800个新的物质,其中包括16000个合成化合物,14800个天然产物。对各国有苗头的药也重复研究。以后历年筛选的工作量
This article focuses on the United States oncology research institutions, especially the National Cancer Institute (NCI) on some of the new anti-cancer clinical research profile for a brief overview. As is known to all, since 1954, NCI has been responsible for organizing and coordinating research on cancer control in various parts of the United States and conducting a large number of screening tests for anti-cancer effects. In 1972 alone, NCI tested 30,800 new substances, including 16,000 synthetic compounds and 14,800 natural products. There are also signs of duplication in countries that have signs of drug abuse. After screening the workload over the calendar year